First-line raltegravir 400 mg BID achieved HIV-1 RNA < 50 copies/mL in 61% of patients vs 66% with efavirenz 600 mg QD, each combined with 3TC/TDF in HIV/TB-coinfected patients receiving rifampin.
Virologic suppression rates and CD4+ cell counts continued to improve through Week 96 in this difficult-to-treat population receiving fostemsavir plus optimized background therapy.
97% of patients receiving long-acting injectable therapy said that they preferred it to continued daily oral ART.
93% of switched patients maintained virologic suppression in study population that included patients with preexisting NRTI, NNRTI, or PI resistance.
In updated birth outcomes surveillance analysis, NTD prevalence slightly higher with DTG vs non-DTG ART (0.3% vs 0.1%; estimated difference: 0.20% to 0.27%).
Differences in pharmacokinetics may account for the trend toward lower HIV infection rates with FTC/TAF vs FTC/TDF as PrEP in MSM and transgender women enrolled on the phase III DISCOVER trial.
Virologic suppression maintained in patients who initiated triple therapy with islatravir + DOR + 3TC, achieved virologic suppression, and then switched to 2-drug therapy with islatravir + DOR.
In phase III study, switch to this dual therapy noninferior to continuing TAF-based triple therapy.
In prespecified secondary analyses, HIV-1 RNA < 50 copies/mL achieved by 86.0% of patients receiving dual therapy vs 89.5% receiving triple-drug ART.
Phase III trial supports use of DTG-based regimens, with low rates of emergent resistance and no INSTI resistance.